
The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.
Van Loon says that oncologists need further research into how often and for how long patients with gastrointestinal cancers should be monitored.
Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.
over 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Canceralmost 11 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCalmost 11 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCalmost 11 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCalmost 11 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC




